Maravai LifeSciences Reports Third Quarter 2026 Financial Results
Business Wire•04/11/2026•16:01 ET
0
Key Highlights
- ➤Q3 revenue $45.9 million, up 10.1% year-over-year
- ➤Full-year revenue guidance raised to $212.0 million-$216.0 million
- ➤Adjusted EBITDA guidance raised to $40.0 million-$42.0 million
- ➤TriLink mRNA revenue increased 28% year-over-year
- ➤Q3 Adjusted EBITDA reached $5.8 million versus $(10.8) million prior year
Expert Statements
Bernd Brust, CEO of Maravai LifeSciences
“Our third-quarter results build on the momentum we established in the first half of the year.”
Bernd Brust, CEO of Maravai LifeSciences
“TriLink revenue grew 12% year-over-year led by 28% revenue growth for our mRNA products, while Cygnus delivered its sixth consecutive quarter of year-over-year growth, with revenue up 8%.”
Bernd Brust, CEO of Maravai LifeSciences
“Four Discovery mRNA customers transitioned to clinical-stage GMP this quarter, reinforcing our belief that today’s Discovery success will create tomorrow’s GMP opportunity.”
Bernd Brust, CEO of Maravai LifeSciences
“Based on our third-quarter performance and our expectations for the fourth quarter, we are raising our full-year revenue and adjusted EBITDA guidance.”
Bernd Brust, CEO of Maravai LifeSciences
“We remain focused on driving sustained, profitable growth and creating long-term value for our shareholders.”
Maravai LifeSciences Reports Third Quarter 2026 Financial Results
Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2026, together with other business updates.
Get started
Create a free account to read the full story.